WWE's signing of Logan Paul in 2022 caught the attention—and ire—of fans who were skeptical of what he'd bring to the table ...

Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases unit had hit the mark in a phase 3 trial, setting it on course for regulatory filings.